Veverimer

Active substance Veverimer
Domain Metabolism and Endocrinology
Reason of inclusion New medicine (specialité)
Main indication Metabolic diseases
Extended indication Metabolic Acidosis Associated With Chronic Kidney Disease

Product

Manufacturer Tricida
Mechanism of action Other
Route of administration Oral
Therapeutical formulation Oral suspension
Budgetting framework Extramural (GVS)
Additional comments Veverimer (TRC101) is a non-absorbed polymer that is designed to bind hydrochloric acid in the GI tract and remove it from the body through excretion in the feces.

Registration

Registration route Centralised (EMA)
Submission date 2020
Expected Registration 2021
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Current treatment options Bicarbonaat
Therapeutic value Potential added value
Substantiation Mogelijke meerwaarde verwacht ten opzichte van huidige behandelopties.
Duration of treatment continuous
Frequency of administration 1 times a day
References NCT03317444

Expected patient volume per year

Patient volume

> 10,000

Market share is generally not included unless otherwise stated.

References Nierstichting; Ortega and Arora. Nefrologia. 2012;32(6):724-30
Additional comments Ruim 10% (1,7 miljoen mensen) van de Nederlandse bevolking heeft chronische nierschade. 40% (680.000 mensen) daarvan weet dat niet. Klachten ontstaan vaak pas als de nierfunctie nog maar 30% is. Hiervan heeft mogelijk 1-2% metabole acidose. Het gaat hier dus mogelijk om meer dan 10.000 patiënten. Het is momenteel onduidelijk of TRC101 behandeling van deze groep geheel gaat vervangen maar dat risico is wel reëel.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension No

Other information

There is currently no futher information available.